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Abstract
Runs of homozygosity (ROH) are extended tracts of adjacent homozygous single nucleotide polymorphisms (SNPs) that are
more common in unrelated individuals than previously thought. It has been proposed that estimating ROH on a genome-
wide level, by making use of the genome-wide single nucleotide polymorphism (SNP) data, will enable to indentify recessive
variants underlying complex traits. Here, we examined ROH larger than 1.5 Mb individually and in combination for
association with survival in 5974 participants of the Rotterdam Study. In addition, we assessed the role of overall
homozygosity, expressed as a percentage of the autosomal genome that is in ROH longer than 1.5 Mb, on survival during a
mean follow-up period of 12 years. None of these measures of homozygosity was associated with survival to old age.
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Introduction
Runs of homozygosity (ROH) are extended tracts of adjacent
homozygous single nucleotide polymorphisms (SNPs) that are
more common in unrelated individuals than previously thought.
Recent evidence has shown that in European populations all
individuals have runs of homozygosity (ROH) shorter than
1.5 Mb, reflecting ancient LD patterns or the chance inheritance
of common haplotypes from both parents, whereas larger ROH
reflect recent parental relatedness or selective advantage [1,2,3].
These large ROHs are likely to be enriched for loci harbouring
functional variants.
To date, a number of studies have analyzed genome-wide SNP
data for ROH and identified individual ROHs that increase the
risk of schizophrenia [1] or Alzheimer’s disease [4], and associate
with height [5] in unrelated individuals. However, for bipolar
disorder [6], colorectal cancer [7] and childhood acute lympho-
blastic leukemia [8] no associations with individual ROH have
been found. Furthermore, no study has reported associations with
overall measures of homozygosity. As for human longevity, it is
likely that recessive alleles that promote longer life exist but have
so far not been identified with genome-wide association studies
(GWAS). Making use of the ROH approach might help to identify
loci harbouring these alleles.
In this study, we examined ROH larger than 1.5 Mb
individually and in combination for association with survival in
5974 participants of the Rotterdam Study. In addition, we assessed
the role of overall homozygosity on survival during a mean follow-
up period of 12 years. None of these measures of homozygosity
was associated with survival to old age.
Results and Discussion
In order to assess the role of ROH in human longevity and to
identify novel longevity loci, we examined overall homozygosity,
and individual ROH regions in the whole genome that are larger
than 1.5 Mb. For this purpose, we made use of the genome-wide
genotype data available in the first and second cohort of the
Rotterdam Study (RS) [9] (Table 1). After quality control 530132
SNPs in 5974 participants were available for subsequent analyses
in the RS1 discovery cohort. Genome-wide ROH were identified
using the Runs of Homozygosity program implemented in PLINK
software [10]. We defined ROH as runs of at least 25 consecutive
homozygous SNPs spanning more than 1.5 Mb with a maximum
gap between two SNPs 100 Kb and a minimum SNP density
coverage of at least 20 SNPs per Kb. As a measure of overall
homozygosity and level of inbreeding, we calculated a percentage
of the autosomal genome that is in ROH longer than 1.5 Mb [2].
Altogether 0.44% (standard deviation (SD) 0.31) of the genome
was in ROH longer than 1.5 Mb in the 5974 participants of RS1.
This percentage is comparable to that reported for other outbred
populations [2]. Of the 5974 participants, 3174 (53%) died during
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the association of genome-wide homozygosity with survival, we
observed no statistically significant association (hazard ratio (HR),
95% confidence interval (CI); 0.95, 0.85–1.07). Even though the
estimate is below unity, suggesting that higher genome-wide
homozygosity is beneficial for survival to old age, the effect size is
too small to be of any relevance.
Next, we assessed the association between individual ROH
regions and survival in RS1. For this analysis all overlapping
ROHs within a region were merged, yielding 1040 regions that
had a frequency higher than 1%. Of these regions nine were
a s s o c i a t e dw i t hs u r v i v a li nR S 1( Table 2). To validate the
existence of these ROH regions and their association with
survival, we made use of the genome-wide SNP data in 1895
participants of RS2 (Table 1). We detected the same ROH
regions also in RS2, but with different frequencies. Further-
more, none of these associated with survival in RS2 (Table 2).
For most estimates the direction was opposite to that observed
in RS1, suggesting that the initial findings arose due to chance.
However, the lack of replication could also stem from the
smaller sample size, shorter follow-up and lower number of
events in the RS2 cohort.
To determine if survival to old age is influenced by the
combination of several ROHs we used the total number of ROH
per individual variable provided in the PLINK output. This
measure takes also infrequent ROHs into account. Altogether
5957 (99.7%) of the participants carried one or more ROH longer
than 1.5 Mb with a maximum of 29 different ROHs per
individual (mean 5.83 ROH, SD 2.62). Despite the inclusion of
infrequent ROH, we observed no association between the number
of ROH per individual and survival (HR, 95% CI; 0.99, 0.98–
1.01).
The lack of associations observed in this study could lie in the
definition of ROH. In this study we used the criteria proposed
by McQuillan R et. al. [2], whereas in other studies different
criteria have been used [4,5,6,7,8]. The most commonly
varying criteria is the length of ROH. In this study we
concentrated on ROH larger than 1.5 Mb, but in other studies
ROH larger than 1.0 Mb [4] or 0.5 Mb [5] have been
analysed. In the latter study, also different minimum number
of SNPs constituting a ROH, and SNP density coverage were
used. To determine whether the results of our study would
change with different ROH definition criteria, we repeated the
analyses using ROH larger than 1.0 Mb and 0.5 Mb, and
setting the number of SNPs constituting a ROH and SNP
density to that used in the study of Yang TL et. al.[5]. However,
also with these definitions of ROH, we did not observe
statistically significant associations between genome-wide ho-
mozygosity and survival (data not shown).
In conclusion, we found no association between survival and
overall homozygosity, and we could not identify ROH regions that
influence survival to old age either individually or cumulatively.
Despite the lack of statistically significant associations, these results
do not exclude the existence of recessive loci that affect survival to
old age. However, it is likely that these loci have small effects and
occur at low frequencies in the general population.
Table 1. Characteristics of the Rotterdam Study (RS).
RS1 RS2
(Discovery cohort) (Replication cohort)
N 5974 1895
Female (n, %) 3547 (59%) 1032 (55%)
Age at baseline in years (mean, SD) 69.4 (9.10) 64.8 (8.03)
Follow-up in years (mean, SD) 12.4 (5.19) 7.62 (1.55)
Mortality (n, %) 3174 (53%) 242 (13%)
doi:10.1371/journal.pone.0022580.t001
Table 2. Association between survival and individual ROH regions.
RS1 RS2
Length SNP Freq Freq
ROH region (KB) (N) (%) HR (95% CI) (%) HR (95% CI)
chr8:68132797–86055273 17923 3313 1.19 1.73 (1.29–2.33) 2.90 0.59 (0.22–1.59)
chr3:49499240–55909341 6410 969 9.73 1.21 (1.08–1.36) 10.6 1.02 (0.66–1.57)
chr3:164109279–170486328 6377 838 1.14 1.49 (1.11–2.00) 2.16 0.77 (0.29–2.06)
chr1:168915903–194976780 26061 3984 7.13 1.17 (1.02–1.35) 10.5 1.12 (0.74–1.70)
chr6:139849739–157503677 17654 3905 1.10 0.66 (0.47–0.94) 3.43 0.92 (0.47–1.80)
chr2:40481216–70916156 30435 6603 1.54 1.34 (1.04–1.72) 4.80 1.00 (0.56–1.78)
chr12:75054501–94547494 19493 3230 4.10 1.20 (1.00–1.43) 7.60 1.14 (0.73–1.79)
chr8:86915545–113724772 26809 4584 1.57 0.73 (0.55–0.98) 13.9 1.18 (0.82–1.69)
chr23:80214069–88330836 8117 610 1.04 1.38 (1.01–1.88) 1.69 1.81 (0.74–4.45)
Cox proportional hazard regression adjusted for sex and age at baseline; *p,0.05; Freq-frequency; HR-hazard ratio; CI-confidence interval.
doi:10.1371/journal.pone.0022580.t002
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Study population
The Medical Ethics Committee of the Erasmus Medical Center
approved the study and written informed consent was obtained
from all participants. The Rotterdam Study (RS) is an ongoing
population-based cohort study on risk factors for chronic diseases
in the elderly. Detailed information on design, objectives and
methods has been presented elsewhere [9]. For this study data
from the first (RS1) and second (RS2) cohort of the Rotterdam
Study were available. In RS1, all inhabitants aged over 55 years
living in the Ommoord district of Rotterdam were invited to
participate. Of these 7983 (78%) agreed to participate. In 1999,
3011 participants (out of 4472 invitees) who had become 55 years
of age or moved into the study district since the start of the study
and were added to the initial cohort (RS2). All participants of the
Rotterdam Study were followed for mortality until January 1
2009. The current study included 5974 participants of the RS1
and 1895 participants of RS2.
Genotyping
The genome-wide genotyping was performed with Illumina
550K array (Illumina, San Diego, CA, USA) in self-reported
individuals of European descent (sample call rate $97.5%).
Individuals with excess of autosomal heterozygosity, mismatch
between genotypic and phenotypic gender, and outliers identified
by the identity-by-state (IBS) clustering analysis were excluded. In
addition, individuals with more than 5% missing genotypes were
excluded. SNPs with a call rate less than 90%, minor allele
frequency (MAF) lower than 1%, or failing Hardy-Weinberg
equilibrium (HWE) at a threshold of p,0.0001 were discarded,
leaving 530132 SNPs for subsequent analyses.
Identification of runs of homozygosity (ROHs)
Genome-wide ROHs were identified using the Runs of
Homozygosity program implemented in PLINK v1.07 software
[10]. PLINK uses a sliding window of minimum 50 SNPs across
the genome to identify ROHs, allowing for five missing SNPs and
one heterozygous site per window. We identified ROHs, which
were at least 1.5 Mb of consecutive homozygous genotypic calls at
adjacent SNP loci, to exclude very common ROHs that occur in
all individuals in all populations [2]. The minimum number of
continuous homozygous SNPs constituting a ROH was set to 25
and the minimum SNP density coverage was set to at least
20 SNPs per Kb, allowing for centromeric and SNP-poor regions
to be algorithmically excluded from analysis. The maximum gap
between two consecutive homozygous SNPs was set at 100 Kb.
Overall homozygosity was calculated by summing the lengths of
all ROH longer than 1.5 Mb and expressing this as a% of the
typed autosomal genome. The ‘‘homozyg-group’’ option in
PLINK was used to create a file of overlapping ROH regions
for each individual.
Statistical analysis
The association between survival and overall homozygosity and
individual ROHs at particular genomic locations and total
number of ROH per individual was conducted by Cox
proportional hazard regression, adjusted for age at baseline and
sex. All association analyses were performed with SPSS version 17
(SPSS Inc, Chicago, IL, USA) statistical software.
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